Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HBB | P68871 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7592031 | 0.79 | FDPS (0.40) | FDPSHDAC1HDAC6LTA4HALDH1A1 | |
| SCHEMBL27535766 | 0.74 | FDPS (0.40) | FDPSHDAC1HDAC6LTA4HALDH1A1 | |
| SCHEMBL1371020 | 0.73 | FDPS (0.40) | FDPSHDAC1HDAC6LTA4HALDH1A1 | |
| SCHEMBL11543167 | 0.73 | FDPS (0.42) | FDPSHDAC1HDAC6LTA4HALDH1A1 | |
| SCHEMBL1079073 | 0.72 | FDPS (0.50) | FDPSHDAC1HDAC6LTA4HALDH1A1 | |
| SCHEMBL11457654 | 0.71 | ADORA2A (0.55) | — | |
| SCHEMBL3210897 | 0.71 | ADORA2A (0.35) | — | |
| SCHEMBL434034 | 0.71 | FDPS (0.44) | FDPSHDAC1HDAC6LTA4HALDH1A1 | |
| SCHEMBL9081767 | 0.70 | HDAC1 (0.40) | FDPSHDAC1HDAC6LTA4HALDH1A1 | |
| SCHEMBL27773228 | 0.69 | FDPS (0.37) | FDPSHDAC1HDAC6LTA4HALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107898790-A | For treating or preventing the antiviral JAK inhibitor of retrovirus and other virus infection | 埃默里大学 | 2018-04-13 | — | — | CN | disclosed |
| CN-107709344-A | For treating the nucleoside analog of flaviviridae and cancer | 共晶制药股份有限公司 | 2018-02-16 | — | — | CN | disclosed |
| CN-107108683-A | 2 ', 2' -dihalonucleoside analogs for the treatment of flaviviridae viruses and cancer | 共晶制药股份有限公司 | 2017-08-29 | — | — | CN | disclosed |
| CN-104185420-B | Antiviral JAK inhibitors for the treatment or prevention of retroviral and other viral infections | 埃默里大学 | 2017-06-09 | — | — | CN | disclosed |
| CN-106661004-A | Potent and selective inhibitors of hepatitis c virus | 共晶制药股份有限公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-104470939-B | D-amino acid compounds for liver diseases | 埃迪尼克斯医药有限责任公司 | 2017-04-26 | — | — | CN | disclosed |
| CN-106536538-A | 2'-disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer | 共晶制药股份有限公司 | 2017-03-22 | — | — | CN | disclosed |
| CN-102803263-B | Purine compounds useful as CB2 agonists | LILLY CO ELI | 2014-12-17 | — | — | CN | disclosed |
| EP-2552916-B1 | PURINE COMPOUNDS USED AS CB2 AGONISTS | LILLY CO ELI (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8710063-B2 | Purine compounds used as CB2 agonists | ELI LILLY AND COMPANY (US) | 2014-04-29 | — | — | US | disclosed |
| EP-2552916-A1 | PURINE COMPOUNDS USED AS CB2 AGONISTS | Eli Lilly and Company (US) | 2013-02-06 | — | — | EP | disclosed |
| US-20120329809-A1 | PURINE COMPOUNDS USED AS CB2 AGONISTS | ELI LILLY AND COMPANY (US) | 2012-12-27 | — | — | US | disclosed |
| CN-102803263-A | Purine compounds useful as CB2 agonists | LILLY CO ELI | 2012-11-28 | — | — | CN | disclosed |
| WO-2011123482-A1 | PURINE COMPOUNDS USED AS CB2 AGONISTS | ELI LILLY AND COMPANY (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329809-A1 | PURINE COMPOUNDS USED AS CB2 AGONISTS | CNR2, CNR1, P2RX7 | FDPS 1522/4885HDAC1 4613/4885HDAC6 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.